MediWound announces marketing approval of NexoBrid in Japan

MediWound announced that its partner, Kaken Pharmaceutical Co., Ltd. has gained marketing approval of NexoBrid in Japan. Kaken Pharmaceutical has the exclusive right to market and distribute NexoBrid in Japan. Kaken Pharmaceutical expects to launch NexoBrid in the summer of 2023. The Japanese Ministry of Health, Labor, and Welfare has granted NexoBrid marketing authorization for non-surgical eschar removal of deep-partial and full-thickness thermal burns for the adult and pediatric population. NexoBrid is approved under the orphan drug designation granted by the MHLW as a priority review for unmet medical needs.